RBR-8t4bf3进行中（未招募）未知

Supplementation of different branched chain amino acids in the treatment of hepatic encephalopathy in cirrhotic patients: randomized, double-blind, controlled trial

Faculdade de Medicina de Botucatu - Universidade Estadual Paulista Julio de Mesquita Filho0 个研究点开始时间: 2016年1月22日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Literate individuals aged over 18 years; Presence of cirrhosis (defined by liver biopsy or by a combination of clinical criteria: physical examination with signs of liver failure and / or portal hypertension, endoscopic examination with the presence of esophageal or gastric varices, and / or radiological imaging, ultrasound or computed tomography abdominal, with evidence of chronic liver disease and / or portal hypertension); Presence of Hepatic Encephalopathy (HE) type C ranging from Minimal Hepatic Encephalopathy (MHE) to grade III.

•Fulminant hepatic failure (Hepatic Encephalopathy type A); Hepatic Encephalopathy (HE) secondary to porto-systemic shunts without intrinsic liver disease (HE type B); Severe neuropsychiatric disorders; Obstruction or inflammatory bowel disease; Severe renal impairment (serum creatinine greater than twice normal); Shock (septic, hemorrhagic, neurogenic, cardiac, anaphylactic or mixed); Misuse of alcohol or alcoholic hepatitis in the last six weeks; Use of food supplement with Branched Chain Amino Acids (BCAA); HE grade IV; Recent use of lactulose, antibiotics or L-ornithine L-aspartate (If these medications are started less than a week of the initial intake of the suplementation, the patient will be temporarily excluded from the study, however, chronic use will not be considered an exclusion criterion); Patients in treatment of hepatitis C; Neoplasia; Pregnancy, Lactation and Obesity.

发起方

Faculdade de Medicina de Botucatu - Universidade Estadual Paulista Julio de Mesquita Filho